Press Releases

GeneCentric Therapeutics to Present New Analyses of Molecular Characterization and Prediction of Treatment Response in Patients with Muscle Invasive Bladder Cancer (MIBC)

New molecular analyses to be presented at ASCO Genitourinary Cancers Symposium Durham, NC, February 13, 2020 – GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.  The data are derived from GeneCentric’s expertise in the identification of RNA-based Predictive […]

GeneCentric Therapeutics Acquires Select ImmunoGenomics

Combined company uniquely suited to drive precision oncology forward with RNA technologies to identify oncology drug responder populations Durham, NC, August 15, 2019 – GeneCentric Therapeutics, Inc. today announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of […]

GeneCentric and Collaborators at Washington University Advance Academic-Industry Head and Neck Cancer Partnership under NCI Grant

Partners to initiate Second Phase of R01-Awarded Research Durham, NC, August 9, 2019 – GeneCentric Therapeutics, Inc. today announced that it has entered the second phase of an academic-industry collaboration with Jose Zevallos MD, MPH, Chief of the Division of Head and Neck Oncologic Surgery in the Department of Otolaryngology at Washington University School of […]

GeneCentric Therapeutics Presents First Data on Novel Response Signatures to Treatment in Muscle Invasive Bladder Cancer (MIBC) Patients

GeneCentric Therapeutics will present the first data on novel response signatures for metastatic, muscle invasive bladder cancer (MIBC) treatments by applying its proprietary, RNA-sequencing based predictive response signature and Cancer Subtyping Platform (CSP®).  The initial response signature and MIBC cohort data are being presented at a poster session at the annual meeting of the American […]

GeneCentric Collaborators from UNC Lineberger Comprehensive Cancer Center Present on Urothelial Cancer at the Genitourinary Cancers Symposium 2019

GeneCentric Therapeutics, Inc. collaborator Dr. Tracy Rose from the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC presented at the Genitourinary Cancers Symposium today on: “Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.” Through a collaboration announced in December 2018 with UNC Lineberger Comprehensive Cancer Center (UNC-LCCC) and […]

GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, President and Chief Executive Officer

CEO Dr. Myla Lai-Goldman named Executive Chairperson Durham, NC, January 3, 2019 -GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Executive Officer and President and will join GeneCentric’s Board of Directors. Dr. Myla Lai-Goldman, founder, current CEO and President, will assume the newly-created role of Executive Chairperson of the […]

GeneCentric Therapeutics Enters Bladder Cancer Research Collaboration with University of North Carolina

Focus is on advancing cancer subtypes to predict disease progression and pursuing immune-biology related drug response biomarkers DURHAM, N.C., December 10, 2018 — GeneCentric Therapeutics, Inc. today announced that it has entered into a research collaboration with the University of North Carolina at Chapel Hill (UNC) to assess patient response to immunotherapeutic drugs such as […]

GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina

Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development DURHAM, N.C., September 24, 2018 — GeneCentric Therapeutics, Inc. today announced that the company has acquired an exclusive license from the University of North Carolina at Chapel Hill (UNC) to technology for subtyping Pancreatic Ductal Adenocarcinoma (PDAC). The company […]

GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, Chief Scientific Officer

GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Scientific Officer (CSO).  Dr. Milburn, who joins GeneCentric from Metabolon, Inc. where he was CSO, has more than 25 years of R&D successful leadership experience in biotechnology companies and in a major pharmaceutical company. “Michael brings a broad range of expertise […]

GeneCentric to Present at the Precision Medicine World Conference 2018

GeneCentric Therapeutics’ CEO, Dr. Myla Lai-Goldman, will deliver a presentation at the Precision Medicine World Conference (PMWC) 2018 Duke University Program, September 24-25, entitled: “Delivering Greater Precision to Precision Medicine.” In an interview with PMWC ahead of the conference Dr. Lai-Goldman provides perspectives on novel cancer drug response biomarkers to enable more effective and efficient drug […]